ClinicalTrials.Veeva

Menu

Electroencephalogram (EEG) Enhanced Transcranial Magnetic Stimulation (eTMS) for Chronic Trauma and Stressor-Related Disorders (TSRD) (ETMS4Stress)

M

Marcia Bockbrader, MD PhD

Status and phase

Enrolling
Phase 3
Phase 2

Conditions

Trauma and Stressor Related Disorders

Treatments

Device: Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)

Study type

Interventional

Funder types

Other

Identifiers

NCT05835414
BEP-001

Details and patient eligibility

About

The goal of this clinical trial is to learn about the safety, feasibility, and preliminary efficacy of EEG-enhanced transcranial magnetic stimulation (eTMS) as an adjunct to standard-of-care therapies for chronic trauma and stressor related disorders (TSRD) among US military veterans.

The main questions the study aims to answer are:

  • Is it safe to provide 30 sessions of eTMS for veterans with chronic TSRD?
  • Is it feasible to provide 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD?
  • Does health-related quality of life improve among veterans after 30 sessions of eTMS as an adjunct to standard-of-care therapies for chronic TSRD?

Participants will undergo 30 sessions of eTMS as an adjunct to standard-of-care therapies for veterans with chronic TSRD, weekly reassessment during treatment, and intermittent follow-up for 36 weeks post-enrollment.

Enrollment

30 estimated patients

Sex

All

Ages

22+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Positive identification as a Veteran per discharge paperwork (DD-214, DD-215, NGB-22, NGB-22A) and photo ID, or Veterans Health Administration Veteran Health Identification Card (VHIC)
  • Presence of deployment-related stressful events (as defined by the Deployment Risk & Resilience Inventory-2, DRRI-2)
  • Trauma event(s) (defined on the Life Experiences Checklist for DSM-5, LEC-5)
  • Presence of 6 months or more of 6 or more "moderate" or worse symptoms from any of the five categories associated with stress disorders as operationalized on the PTSD Checklist for DSM-5 (PCL-5; intrusion, altered mood and cognitions, dissociation, avoidance, and arousal).
  • Informed consent for study participation, off label-eTMS, and data use
  • Enrollment in addiction services, if meets standard addiction treatment criteria
  • Enrollment in opioid reduction services, if dependent on opioids and morphine equivalent daily dose exceeds 50 mg (50 morphine equivalent daily dose, MEDD)
  • Agreement to limit daily alcoholic beverage consumption to no more than 2 servings
  • Signed pain contract, if MEDD >= 80, per State of Ohio prescribing guidelines

Exclusion criteria

  • Uncontrolled medical, psychological or neurological conditions including, but not limited to:
  • Uncontrolled psychosis or mania
  • Uncontrolled seizure disorder or EEG abnormalities that indicate risk of seizure, i.e., epileptiform discharges during the EEG recording
  • Uncontrolled cardiac, pulmonary, or endocrine disorder (e.g., diabetes)
  • Acute pain or illness
  • Active, untreated addiction to prescription drugs, alcohol or illicit substances (not including cannabis or derivatives, which are available in many states under medical prescription or for recreational use)
  • Clinically significant medical condition or abnormality that in the Investigator's judgment might pose a potential safety risk to the subject or limit the interpretation of the trial results
  • Pregnant, or female unwilling to use effective birth control during the course of the trial (unless cleared for participation by obstetrician/gynecologist)
  • Absolute contraindications to TMS: Presence of aneurysm clips or coils, cochlear or ocular implant, cortical epidural stimulator, deep brain stimulator, pacemaker or defibrillator, retained intracranial metal foreign body (bullets, shrapnel - excluding titanium and oral implants), steel stents or shunts, active vagal nerve stimulator, ventriculoperitoneal (VP) shunt.
  • Prior TMS treatment
  • Unwilling or unable to adhere to the study treatment, data collection schedule, or study procedures

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Adjunctive eTMS treatment (no delay)
Experimental group
Description:
6 weeks (30 sessions) of daily eTMS as an adjunct to standard of care TSRD treatment
Treatment:
Device: Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Neil B Austin; Marcia A Bockbrader, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems